We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS-FDA PARALLEL PRODUCT REVIEWS RAISE DRUG INDUSTRY CONCERNS
CMS-FDA PARALLEL PRODUCT REVIEWS RAISE DRUG INDUSTRY CONCERNS
January 21, 2005
The agreement between the FDA and the Centers from Medicare & Medicaid Services (CMS) to conduct parallel reviews of products — which would allow drugmakers to receive both a drug approval and reimbursement coverage simultaneously — could speed some products to market, but it also raises concerns for the pharmaceutical industry, according to experts.